ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABBV is a good buy right now for a beginner long-term investor with $50,000-$100,000 to invest. My view is a cautious buy: the stock has strong long-term fundamentals, solid dividend support, and broad analyst support, while the current price is near technical support and not showing an overheated setup. Because the user is impatient and wants a direct answer, I would buy it now rather than wait for a perfect pullback. The strongest case is the company’s durable immunology franchise and consistent dividend growth; the main offset is that near-term earnings were weaker than revenue growth, so this is better as a long-term core position than a short-term trade.
ABBV closed at 203.5 after a 1.13% regular-session decline, with pre-market also slightly negative. The stock is trading very close to its pivot level of 203.127, which suggests the market is at an important decision point. RSI_6 at 42.1 is neutral-to-soft, not oversold, but also not stretched. MACD histogram remains positive at 0.681, though it is contracting, which points to slowing momentum rather than a breakdown. Moving averages are converging, implying a consolidation phase. Support sits at 193.913, with resistance at 212.341. Overall, the trend is mildly constructive but not strongly bullish in the immediate term; still, the current area is reasonable for a long-term entry.
["Q1 revenue rose 12.43% year over year to $15.0B, showing strong top-line growth.", "News highlighted 12.4% revenue growth in Q1 driven by strong immunology sales.", "AbbVie declared a quarterly dividend of $1.73 per share, reinforcing its long dividend-growth record.", "Analysts broadly remain positive, with multiple Buy/Outperform/Overweight ratings and higher price targets.", "BofA upgraded the stock to Buy, citing overdone concerns around immunology competition and durable growth into the mid-2030s."]
["Net income fell 45.53% year over year in the latest quarter.", "EPS dropped 45.83% year over year, which weakens near-term earnings quality.", "The MACD histogram is still positive but contracting, showing momentum is fading.", "Congress trading data shows one recent sale and no purchases, which leans cautious.", "Short-term pattern analysis suggests limited immediate upside and some downside drift over the next month."]
In Q1 2026, AbbVie delivered strong revenue growth of 12.43% year over year to $15.0B, which is the latest quarter season available. Gross margin improved to 71.88%, a positive sign for business quality and pricing power. However, net income fell 45.53% and EPS dropped 45.83%, so earnings did not keep pace with sales growth. That means the quarter was strong on growth and margins, but weaker on bottom-line conversion.
Analyst sentiment is clearly positive. Recent actions include Evercore ISI raising its target to $236 and keeping Outperform, Morgan Stanley raising to $278 with Overweight, BofA upgrading to Buy with a $234 target, Canaccord initiating Buy with a $262 target, Piper Sandler keeping Overweight with a $294 target, and Guggenheim raising to $249 with Buy. The overall Wall Street view is constructive: pros like AbbVie’s durable immunology franchise, visible long-term growth, and dividend strength. The main con is ongoing concern about competitive erosion in immunology and the need for continued pipeline execution. Net-net, the pros outweigh the cons for a long-term investor.
